TD Cowen analyst Marc Frahm reiterated a Buy rating on Xilio Therapeutics Inc (NASDAQ: XLO).The analyst commented, "XLO reported Q2 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE